Dedes KJ
Dedes KJ
University Hospital of Zurich
Verified email at usz.ch
TitleCited byYear
Emerging therapeutic targets in endometrial cancer
KJ Dedes, D Wetterskog, A Ashworth, SB Kaye, JS Reis-Filho
Nature Reviews Clinical Oncology 8 (5), 261-271, 2011
2372011
PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors
KJ Dedes, D Wetterskog, AM Mendes-Pereira, R Natrajan, MB Lambros, ...
Science Translational Medicine 2 (53), 53ra75-53ra75, 2010
2232010
Down-regulation of the miRNA master regulators Drosha and Dicer is associated with specific subgroups of breast cancer
KJ Dedes, R Natrajan, MB Lambros, FC Geyer, MA Lopez-Garcia, ...
European Journal of Cancer 47 (1), 138-150, 2011
1542011
Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
KJ Dedes, PM Wilkerson, D Wetterskog, B Weigelt, A Ashworth, ...
Cell Cycle 10 (8), 1192-1199, 2011
1422011
Functional viability profiles of breast cancer
R Brough, JR Frankum, D Sims, A Mackay, AM Mendes-Pereira, I Bajrami, ...
Cancer Discovery 1 (3), 260-273, 2011
1392011
Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer
MD Forster, KJ Dedes, S Sandhu, S Frentzas, R Kristeleit, A Ashworth, ...
Nature Reviews Clinical Oncology 8 (5), 302-306, 2011
1022011
ARID1A Mutations and PI3K/AKT Pathway Alterations in Endometriosis and Endometriosis-Associated Ovarian Carcinomas
EP Samartzis, A Noske, KJ Dedes, D Fink, P Imesch
International Journal of Molecular Sciences 14 (9), 18824-18849, 2013
1012013
Impact of clinical pathways in surgery
MK Müller, KJ Dedes, D Dindo, S Steiner, D Hahnloser, PA Clavien
Langenbeck's archives of surgery 394 (1), 31-39, 2009
842009
Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast
R Natrajan, PM Wilkerson, C Marchiò, S Piscuoglio, CKY Ng, P Wai, ...
The Journal of Pathology, 2014
752014
Loss of ARID1A expression sensitizes cancer cells to PI3K-and AKT-inhibition
EP Samartzis, K Gutsche, KJ Dedes, D Fink, M Stucki, P Imesch
Oncotarget 5 (14), 5295-5303, 2014
742014
Loss of ARID1A/BAF250a-expression in endometriosis: a biomarker for risk of carcinogenic transformation?
EP Samartzis, N Samartzis, A Noske, A Fedier, R Caduff, KJ Dedes, ...
Modern Pathology 25 (6), 885-892, 2012
732012
Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation
KJ Dedes, K Matter-Walstra, M Schwenkglenks, BC Pestalozzi, D Fink, ...
European Journal of Cancer 45 (8), 1397-1406, 2009
732009
Management and costs of treating lung cancer patients in a university hospital
KJ Dedes, TD Szucs, S Bodis, M Joerger, A Lowy, EW Russi, HC Steinert, ...
Pharmacoeconomics 22 (7), 435-444, 2004
622004
A cost-effectiveness analysis of nivolumab versus docetaxel for advanced non-squamous non-small cell lung cancer including PD-L1 testing
K Matter-Walstra, M Schwenkglenks, S Aebi, K Dedes, J Diebold, ...
Journal of Thoracic Oncology, 2016
59*2016
Cost-effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a model-based analysis of the HERA and FinHer trial
KJ Dedes, TD Szucs, P Imesch, A Fedier, MK Fehr, D Fink
Annals of oncology 18 (9), 1493-1499, 2007
592007
Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland
TD Szucs, N Largeron, KJ Dedes, R Rafia, S Bénard
Current Medical Research and Opinion® 24 (5), 1473-1483, 2008
572008
PPM1D gene amplification and overexpression in breast cancer: a qRT-PCR and chromogenic in situ hybridization study
MB Lambros, R Natrajan, FC Geyer, MA Lopez-Garcia, KJ Dedes, ...
Modern Pathology 23 (10), 1334-1345, 2010
522010
The histone deacetylase inhibitors suberoylanilide hydroxamic (Vorinostat) and valproic acid induce irreversible and MDR1-independent resistance in human colon cancer cells
A Fedier, KJ Dedes, P Imesch, AO Von Bueren, D Fink
International journal of oncology 31 (3), 633-641, 2007
502007
Effect of MRE11 Loss on PARP-Inhibitor Sensitivity in Endometrial Cancer In Vitro
R Koppensteiner, EP Samartzis, A Noske, A von Teichman, I Dedes, ...
PloS one 9 (6), e100041, 2014
462014
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial
M Colleoni, W Luo, P Karlsson, J Chirgwin, S Aebi, G Jerusalem, P Neven, ...
The Lancet Oncology, 2017
392017
The system can't perform the operation now. Try again later.
Articles 1–20